Saturday, July 11, 2026

pharma · Diarrhea-predominant Irritable Bowel Syndrome

Chengdu University of

Chengdu University of drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

CN HQ
256 Employees
NMPA registrant Type
Company details
Status
Public
HQ
CN
Employees
256
Programs
1
Drugs
1
Patents
0
Intelligence · Drug Pipeline

Chengdu University of pipeline

Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Chengdu University of drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

1 compounds
  1. Development asset linked to Chengdu University of in public FDA and regional records. Mechanism: Mu opioid receptor agonist.

    Mechanism
    Mu opioid receptor agonist